Pacer Advisors Inc. Decreases Stock Position in Corteva, Inc. $CTVA

Pacer Advisors Inc. trimmed its position in shares of Corteva, Inc. (NYSE:CTVA) by 2.7% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,289,146 shares of the company’s stock after selling 64,588 shares during the quarter. Pacer Advisors Inc.’s holdings in Corteva were worth $191,624,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the company. Drummond Knight Asset Management Pty Ltd purchased a new stake in Corteva in the 4th quarter worth about $25,713,000. Arbejdsmarkedets Tillaegspension purchased a new position in shares of Corteva during the fourth quarter valued at approximately $23,679,000. Leonteq Securities AG bought a new position in shares of Corteva during the fourth quarter valued at approximately $2,350,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Corteva by 23.5% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 110,075 shares of the company’s stock worth $7,378,000 after buying an additional 20,957 shares during the period. Finally, Brandes Investment Partners LP raised its holdings in shares of Corteva by 1.1% in the fourth quarter. Brandes Investment Partners LP now owns 2,312,515 shares of the company’s stock worth $155,009,000 after buying an additional 24,985 shares during the period. Institutional investors own 81.54% of the company’s stock.

Corteva Stock Up 0.3%

Shares of NYSE:CTVA opened at $78.98 on Monday. Corteva, Inc. has a 52-week low of $60.53 and a 52-week high of $90.97. The stock has a market cap of $52.83 billion, a P/E ratio of 52.31, a price-to-earnings-growth ratio of 2.39 and a beta of 0.57. The business’s 50 day moving average is $82.15 and its 200 day moving average is $79.63. The company has a quick ratio of 1.10, a current ratio of 1.52 and a debt-to-equity ratio of 0.07.

Corteva (NYSE:CTVA) last issued its earnings results on Thursday, July 30th. The company reported $2.30 earnings per share for the quarter, beating analysts’ consensus estimates of $2.24 by $0.06. The business had revenue of $6.38 billion during the quarter, compared to analyst estimates of $6.60 billion. Corteva had a return on equity of 10.18% and a net margin of 5.66%.Corteva’s revenue was down 1.2% on a year-over-year basis. During the same period in the previous year, the company posted $2.20 EPS. Corteva has set its FY 2026 guidance at 3.600-3.800 EPS. Sell-side analysts predict that Corteva, Inc. will post 3.75 EPS for the current year.

Corteva Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 15th. Stockholders of record on Tuesday, September 1st will be paid a dividend of $0.18 per share. The ex-dividend date is Tuesday, September 1st. This represents a $0.72 annualized dividend and a dividend yield of 0.9%. Corteva’s dividend payout ratio (DPR) is currently 47.68%.

Trending Headlines about Corteva

Here are the key news stories impacting Corteva this week:

• Positive Sentiment: Corteva reported second-quarter adjusted EPS of $2.30, exceeding the $2.24 analyst consensus and rising from $2.20 a year earlier. Seed pricing, productivity improvements, demand for newer genetics and traits, and growth in Crop Protection products supported margins. Reuters earnings report
• Positive Sentiment: The company raised its fiscal 2026 EPS outlook to $3.60-$3.80, reflecting strong first-half performance, operating improvements and growth platforms. Management also said it remains on track for the planned October 1 Vylor spin-off, a potential catalyst for improved business focus and valuation. Corteva first-half results and outlook
• Positive Sentiment: Analyst commentary remains broadly constructive: Corteva has outperformed the broader market and agriculture-focused ETFs, while brokerages maintain a consensus “Moderate Buy” rating. Momentum-focused analysis also highlights the company’s improving execution and fundamentals. Brokerage consensus rating
• Neutral Sentiment: Despite the earnings beat and higher guidance, one analysis argues that much of Corteva’s improved execution is already reflected in the stock, leaving limited upside unless earnings growth accelerates. Corteva valuation analysis
• Negative Sentiment: Second-quarter revenue was $6.38 billion, below the $6.60 billion consensus and down 1.2% year over year. The sales miss, together with competitive pricing pressure, appears to be the main reason the stock moved lower despite the profit beat and raised outlook. Corteva second-quarter earnings summary

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. Oppenheimer boosted their price objective on Corteva from $89.00 to $95.00 and gave the company an “outperform” rating in a report on Thursday, July 23rd. UBS Group reduced their target price on Corteva from $90.00 to $86.00 and set a “neutral” rating on the stock in a research note on Tuesday, June 9th. Mizuho lifted their target price on Corteva from $96.00 to $97.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 14th. Royal Bank Of Canada boosted their target price on shares of Corteva from $97.00 to $103.00 and gave the company an “outperform” rating in a research note on Tuesday, July 21st. Finally, CICC Research upped their price target on shares of Corteva from $80.00 to $93.00 and gave the stock an “outperform” rating in a report on Wednesday, May 13th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $90.19.

About Corteva

Corteva, Inc (NYSE: CTVA) is an independent global agriculture company that was established as a publicly traded firm in mid‑2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva’s operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.

Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.